Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...
1don MSN
Google Doodle turns spotlight on the quadratic equation: The formula behind every curve explained
Google's latest doodle in India celebrates the quadratic equation, ax² + bx + c = 0, showcasing its real-world applications ...
One of the most common genetic diseases, AATD, involves the retention of misfolded alpha 1 antitrypsin (AAT) in hepatocytes, ...
MedPage Today on MSN
Two Kidney Function Measures Are Not Always Aligned With Each Other
Unlike creatinine, plasma levels of cystatin C are not affected by muscle mass, said Sarav and Alpern. However, cystatin C -- which also comes at a higher cost -- can increase with inflammation, ...
The FDA and CDC, in collaboration with the Infant Botulism Treatment and Prevention Program (IBTPP), and state and local partners, are investigating a multistate outbreak of 13 infant botulism ...
Vertex Pharmaceuticals Incorporated today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the ...
The bug exposes the Metro development server to remote attacks, allowing arbitrary OS command execution on developer systems ...
We’ve sifted through early Black Friday offers to highlight the best vacuum deals we’ve come across so far, so you can find a high-performing model without the premium price tag. Our favorite upright ...
The ASX drifted higher at lunch as tech stocks did the heavy lifting. Meanwhile gold hit new highs and a mixed bag from ANZ ...
Learn Paste Special math, Flash Fill patterns, Go To Special filters, and the F4 shortcut to clean data fast and share Excel ...
Thank you, operator. Hello, and welcome, everyone. Today's earnings call will be led by Dr. Samantha Du, Zai Lab's Founder, CEO and Chairperson. She will be joined by Josh Smiley, President and Chief ...
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback